Literature DB >> 33355997

Use of cardiac radiation therapy as bridging therapy to CAR-T for relapsed pediatric B-cell acute lymphoblastic leukemia.

Cesar P Marquez1,2, Raul Montiel-Esparza3, Caressa Hui2, Liora M Schultz3, Kara L Davis3, Richard T Hoppe2, Sarah S Donaldson2, Sneha Ramakrishna3, Susan M Hiniker2.   

Abstract

The use of radiotherapy as bridging therapy to chimeric antigen receptor T-cell therapy (CAR-T) in pre-B acute lymphoblastic leukemia (B-ALL) has been minimally explored. Here, we present a boy with B-ALL who relapsed after allogeneic bone marrow transplant with disseminated disease, including significant symptomatic cardiovascular and gastrointestinal (GI) involvement. The cardiac and GI leukemic infiltrates were successfully treated with bridging radiation therapy (BRT) prior to CAR-T infusion. Using this approach, he successfully tolerated CAR-T with no evidence of disease or sequelae on 3-month follow-up. This is the first reported case of safe and effective delivery of cardiac BRT in B-ALL.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  B-ALL; CAR-T; pediatric oncology; radiotherapy

Year:  2020        PMID: 33355997     DOI: 10.1002/pbc.28870

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  3 in total

1.  Adjuvant Scrotal Radiation Therapy As Bridging Therapy to Chimeric Antigen Receptor T-Cell Following Extramedullary Relapse in B-Cell Acute Lymphoblastic Leukemia.

Authors:  Colton Ladbury; Amandeep Salhotra; Savita Dandapani
Journal:  Cureus       Date:  2021-12-03

2.  Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy.

Authors:  Elizabeth M Holland; Bonnie Yates; Alex Ling; Constance M Yuan; Hao-Wei Wang; Maryalice Stetler-Stevenson; Michael LaLoggia; John C Molina; Daniel A Lichtenstein; Daniel W Lee; John A Ligon; Haneen Shalabi; Mark A Ahlman; Nirali N Shah
Journal:  Blood Adv       Date:  2022-04-12

Review 3.  Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.

Authors:  Xinyi Xiao; Yazhuo Wang; Zhengbang Zou; Yufei Yang; Xinyu Wang; Xin Xin; Sanfang Tu; Yuhua Li
Journal:  Front Immunol       Date:  2022-08-23       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.